GABBR2 Polyklonale Antilichaam, APC-Cy7 Vervoeging

Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2. Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis. Plays a critical role in the fine-tuning of inhibitory synaptic transmission. Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials. Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception.

HG20; GPR51; GPRC3B; GABABR2; HRIHFB2099; Gamma-aminobutyric acid type B receptor subunit 2; GABA-B receptor 2; GABA-B-R2; GABA-BR2; Gb2; G-protein coupled receptor 51; GABBR2

9568

O75899

Cytoplasm, Cell membrane

Human, Mouse, Rat

501-650/941

GABBR2

APC-Cy7

KLH conjugated synthetic peptide derived from human GABA B Receptor 2

WB, IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

650nm/780nm

1µg/µl

WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

9568

Dog, Cow, Horse, Chicken, Rabbit